Wednesday, June 10, 2026

Patent intelligence · WO

WO 2025114603

COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES

granted A61K 31/ 496 A IA61K 31/ 506 A IA61K 31/ 555 A IA61K 31/ 4196 A I
Status granted
Pipeline programs 2
Years to expiry 19
Applicant portfolio 25
Patent details — WO 2025114603
Jurisdiction
WO
Status
granted
Grant date
Jun 5, 2025
Expiration
May 31, 2045
CPC classes
A61K 31/ 496 A I, A61K 31/ 506 A I, A61K 31/ 555 A I, A61K 31/ 4196 A I
View on Google Patents ↗

Quick answer

WO 2025114603 (COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES) is held by BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]. Status: granted. Granted Jun 5, 2025. Expires May 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 496 A I, A61K 31/ 506 A I, A61K 31/ 555 A I, A61K 31/ 4196 A I, A61K 31/ 4439 A I, A61K/314196

More from BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]

Related pharmaceutical patents in our USPTO index.

  1. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Expires May 16, 2046

    granted
  2. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Apr 11, 2046

    granted
  3. US 20260042800

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Feb 7, 2046

    granted
  4. WO 2024094329

    PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires May 5, 2044

    granted
  5. CA 3268414

    MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Apr 13, 2044

    granted
  6. AU 2022323463

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Expires Feb 24, 2044

    granted
  7. AR 127448

    DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Expires Jan 19, 2044

    granted

Frequently asked questions

What is US patent 2025114603?

WO 2025114603 (COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES) is held by BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH]. Status: granted. Granted Jun 5, 2025. Expires May 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2025114603?

BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2025114603 expire?

Our index shows an expiration date of May 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.